elevance health inc. - ELV
ELV
Close Chg Chg %
397.57 6.04 1.52%
Pre-Market
403.61
+6.04 (1.52%)
Volume: 1.38M
Last Updated:
Nov 21, 2024, 3:59 PM EDT
Company Overview: elevance health inc. - ELV
ELV Key Data
| Open $399.15 | Day Range 397.82 - 403.83 |
| 52 Week Range 391.22 - 567.17 | Market Cap $92.18B |
| Shares Outstanding 231.92M | Public Float 231.45M |
| Beta 0.85 | Rev. Per Employee N/A |
| P/E Ratio 14.49 | EPS $27.61 |
| Yield 160.26% | Dividend $1.63 |
| EX-DIVIDEND DATE Dec 5, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.99M |
ELV Performance
| 1 Week | 0.73% | ||
| 1 Month | -5.10% | ||
| 3 Months | -26.08% | ||
| 1 Year | -15.69% | ||
| 5 Years | 38.30% |
ELV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
22
Full Ratings ➔
An error occurred while fetching the data.
An error occurred while fetching the data.
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 514.722 | |
| Number of Ratings | 22 | Current Quarters Estimate | 3.979 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 33.18 | |
| Last Quarter’s Earnings | 8.37 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 33.14 | Next Fiscal Year Estimate | 34.952 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 19 | 16 | 20 | 20 |
| Mean Estimate | 3.98 | 10.32 | 33.18 | 34.95 |
| High Estimates | 6.92 | 11.70 | 37.29 | 41.53 |
| Low Estimate | 3.00 | 8.34 | 32.18 | 31.45 |
| Coefficient of Variance | 18.61 | 10.06 | 2.97 | 4.95 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 14 |
| OVERWEIGHT | 4 | 4 | 4 |
| HOLD | 4 | 4 | 6 |
| UNDERWEIGHT | 1 | 1 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Elevance Health Inc. - ELV
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Elevance Health Inc. - ELV
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 23, 2024 | Robert L. Dixon Director | 9,721 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $506.76 per share | 4,926,213.96 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | 2,043 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | 27,304 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $532.68 per share | 14,544,294.72 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | 30,738 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $532.14 per share | 16,356,919.32 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | 33,503 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $238.27 per share | 7,982,759.81 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | 45,571 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $238.27 per share | 10,858,202.17 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | 31,560 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $533.73 per share | 16,844,518.80 |
| Apr 26, 2024 | Felicia Farr Norwood EVP & President,Gov Health Ben | 31,460 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $534.74 per share | 16,822,920.40 |
| Mar 13, 2024 | Morgan Kendrick EVP & President, Commercial | 15,840 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $500.46 per share | 7,927,286.40 |
| Mar 11, 2024 | Ronald William Penczek CAO & Controller | 1,764 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $504.58 per share | 890,079.12 |
| Mar 6, 2024 | Mark Kaye EVP & CFO | 10,633 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Mark Kaye EVP & CFO | 23,031 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Ratnakar Lavu EVP & Chief Digital Officer | 6,765 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Gail Koziara Boudreaux President and CEO; Director | 160,709 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Gail Koziara Boudreaux President and CEO; Director | 126,192 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 13,425 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $499.11 per share | 6,700,551.75 |
| Mar 6, 2024 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 15,830 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2024 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 39,982 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $166.97 per share | 6,675,794.54 |
| Mar 6, 2024 | Peter David Haytaian EVP & Pres Carelon & CarelonRx | 35,776 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $500.18 per share | 17,894,439.68 |